Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sanofi Japan Sales Rise 4.5% in 2025 as Dupixent Widens Label
April 15, 2026
-
REGULATORY Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
-
BUSINESS AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances
April 13, 2026
-
BUSINESS MSD Japan Eyes Up to 8 Approvals, 8-Plus Filings under New Chief
April 10, 2026
-
REGULATORY Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two
April 9, 2026
-
BUSINESS Rising Costs Squeeze Generic Firms, Spur Calls for Unprofitable Drug Re-Pricing in 2027
April 8, 2026
-
BUSINESS BMS Files to Fully Localize Breyanzi Production in Japan
April 8, 2026
-
REGULATORY Uncertainty Clouds Start of 6-Month CEA “Technical Discussions”
April 7, 2026
-
REGULATORY Pfizer Japan Chief Urges Applying 9.6% Growth Target to Domestic Market
April 7, 2026
-
BUSINESS Drug Makers Keep New Grad Hiring Largely Flat as Sales Rep Hiring Picks Up
April 6, 2026
-
BUSINESS Japan Drug Makers Vetting Impact as Trump Unveils Tariff Details
April 6, 2026
-
REGULATORY Trump Signs Off on Up to 100% Tariffs on Drugs; Japan Rate Set at 15%
April 3, 2026
-
BUSINESS Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
-
BUSINESS Human Judgment Still Key in the AI Era, Pharma Leaders Tell New Recruits
April 2, 2026
-
BUSINESS Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
April 1, 2026
-
ORGANIZATION JMA’s Ezawa Calls for “National Debate” on Drug Policy
March 31, 2026
-
ACADEMIA Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
March 30, 2026
-
BUSINESS Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
March 30, 2026
-
REGULATORY Japan Ranks 9th Among 10 in AI Analysis of EFPIA Pharma Strategy Report
March 27, 2026
-
BUSINESS Takeda Unveils Annual 200 Billion Yen Cost Savings by FY2028
March 26, 2026
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…